

ASX Announcement | 22 April 2024  
Althea Group Holdings (ASX: AGH)

## Althea announces distribution agreement with Symbion

### Highlights:

- Althea announces a distribution agreement with Symbion, a national wholesaler of healthcare services and products, with over 3,850 retail pharmacy customers and 1,350 hospital customers across Australia
- This key strategic milestone will see Althea's complete portfolio of medicinal cannabis products distributed through the well-established pharmaceutical wholesale channel from 22<sup>nd</sup> April 2024
- The medicinal cannabis market in Australia continues to grow with over 1 million patients treated since 2016

22 April 2024: **Althea Group Holdings Limited (ASX:AGH) ('AGH', or 'the Company')**, a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products, is delighted to announce its strategic agreement with Symbion for the distribution of Althea's portfolio of pharmaceutical cannabis products across Australia.

### About Symbion

Symbion is a national wholesaler of healthcare services and products with over 3,850 retail pharmacy customers and 1,350 hospital customers across Australia.

Symbion has 10 warehouses located around Australia which coordinate daily deliveries and houses over 17,000 product lines from more than 550 manufacturing partners.

Symbion's online SHOP portal, available on any device, makes ordering simple. Pharmacies and hospitals have complete control over their account and a bird's eye view of stock levels, order tracking, invoices, back orders and more.

Under the distribution agreement, Symbion will distribute Althea's complete portfolio of medicinal cannabis products from 22<sup>nd</sup> April 2024.

### Australian medicinal cannabis market overview

Around 1 million patients have been treated with medicinal cannabis through the authorised prescriber and special access schemes since 2016.

Medicinal cannabis products are most commonly prescribed in Australia for conditions such as pain, anxiety and sleep disorders after standard medical therapies have failed, which represents a significant unmet medical need.

The potential therapeutic benefit of medicinal cannabis is becoming more widely recognised with around 60% of doctors in Australia reporting patient enquiries in the last 3 months.

As the industry continues to grow, the importance of a robust and mainstream distribution network becomes increasingly important to normalise and simplify the way patients access cannabis-based medicines.

### Althea's mission and vision for growth



Althea is an industry leader in the manufacturing, sales and distribution of cannabis-based medicines and is recognised as a leading company in the Australian market. Since 2018, Althea has remained committed to the supply of pharmaceutical-grade, GMP-finished medicinal cannabis products, and continues to drive innovation in the marketplace, including the recent launch of its innovative range of full-spectrum softgel capsules.

Althea has a clear purpose to normalise and simplify medicinal cannabis prescribing and therefore the strategic alignment with Symbion is a key milestone, bringing together Australia's leading supplier of cannabis extracts and Australia's largest pharmaceutical wholesaler.

The partnership ensures that doctors, pharmacists, and patients can quickly and simply access Althea's range of medicinal cannabis products.

**AGH CEO and Managing Director, Joshua Fegan said:** "The strategic agreement with Symbion is an exciting landmark for Althea as we begin distribution through such a well-established pharmaceutical wholesaler. The strong growth of the medicinal cannabis market in Australia highlights the therapeutic benefit that patients may gain from Althea products. By partnering with Symbion, we push forward in our mission to normalise and simplify access to medicinal cannabis, ensuring doctors can prescribe and pharmacies can dispense cannabis-based medicines as they would any other pharmaceutical product."

-ENDS-

*Authorised by: Robert Meissner, Company Secretary*

**For further information, please contact:**

**Althea Group Holdings Ltd**

**Joshua Fegan**

CEO & Managing Director

**M:** 1300 70 20 20

**E:** [contact@althea.life](mailto:contact@althea.life)

**Media & Investor Enquiries**

Media & Investor Relations

**P:** +613 9650 5096

**E:** [investors@althea.life](mailto:investors@althea.life)

**Althea Group Holdings Limited (ASX:AGH)**

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products purchased by adult consumers in retail stores.

AGH operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more about Althea Group Holdings, please visit: [www.altheagroupholdings.com](http://www.altheagroupholdings.com)

For more information on Peak, please visit: [www.peakprocessing.com](http://www.peakprocessing.com)

For more information on Althea, please visit: [www.althea.life](http://www.althea.life)

